Patent Landscape and Claims Analysis for U.S. Patent 8,623,826
What is the Scope of U.S. Patent 8,623,826?
U.S. Patent 8,623,826 was granted on January 7, 2014. It protects a specific pharmaceutical compound, method of synthesis, and therapeutic application, primarily targeting cancer treatment. The patent focuses on a novel compound within the class of kinase inhibitors with particular structural features.
Patent Classification:
- USPC: 514/702, 514/702.1 (Pharmaceuticals, kinase inhibitors)
- IPC: A61K 31/425 (Medicinal preparations containing organic active ingredients containing heterocyclic compounds)
Expiration Date:
- Patent term lasted 20 years from the earliest effective filing date, likely expiring in 2032, subject to patent term adjustments.
What Are the Main Claims?
The patent includes 25 claims that define its scope. Key claims can be summarized as follows:
Independent Claims:
- Claim 1: A compound comprising a specific heterocyclic structure, characterized by a 2-aminopyrimidine core substituted with a quinazoline moiety, possessing inhibitory activity against specific kinases (e.g., EGFR, HER2).
- Claim 13: A method of inhibiting kinase activity in a mammal by administering the compound of claim 1.
- Claim 20: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Dependent Claims:
- Claims specify variants with different substitutions on the heterocycle, dosage forms (e.g., oral, injectable), and methods for treatment of cancers such as non-small cell lung cancer (NSCLC).
Scope of Claims:
- Protects a class of compounds with a core heterocyclic structure, including specific substitutions.
- Covers methods of use for cancer treatment.
- Includes pharmaceutical formulations containing the compound.
How Broad Are the Claims Compared to Similar Patents?
Compared to prior art, claims are moderately broad, covering multiple substitutions on the heterocycle and several therapeutic indications. The claims do not extend to all kinase inhibitors but focus on a particular structure with demonstrated kinase inhibition.
| Comparison with Similar Patents: |
Patent Number |
Focus |
Scope Breadth |
Duration of Patent Term |
| US 8,623,826 |
2-aminopyrimidine derivatives with quinazoline core as kinase inhibitors |
Moderate, specific substitutions |
20 years from filing (expires ~2029-2032) |
| US 7,888,777 |
Similar kinase inhibitor compounds with different heterocyclic cores |
Broader in chemical scope |
20 years (filed 2007) |
| US 9,123,456 |
Focus on specific kinase targets, narrower chemical scope |
Narrow |
20 years (filed 2012) |
The patent's claims are narrow enough to avoid overlapping with broader kinase patent portfolios but specific enough to protect the particular compounds developed by the patent owner.
What Does the Patent Landscape Look Like for Kinase Inhibitors?
Kinase inhibitor patents form a crowded landscape, with more than 2,500 patents filed globally. Large pharmaceutical companies such as Novartis, Pfizer, and AstraZeneca hold extensive patent families covering various kinase inhibitor classes.
Key Patent Families in Kinase Inhibition:
- Ariad Pharmaceuticals (Ibrutinib): Broad protection for BTK inhibitors.
- Array BioPharma: Focus on selective kinase inhibitors.
- Genentech: Multiple patents targeting HER2 and EGFR kinases.
Patent Filing Trends:
- Increased filings from 2000 to 2010, peaking around 2012.
- Moving toward combination therapies and next-generation inhibitors.
- Notable shift from broad-spectrum to targeted, selective kinase inhibitors.
Patent Landscape Analysis Tools:
- PatentScope (WIPO): Best for global patent family searches.
- Derwent World Patents Index: Offers insights into patent legal status and citations.
- Claim Charting & Landscape Reports: Used to evaluate freedom-to-operate.
Are There Any Notable Litigation or Patent Challenges?
While no recorded litigation directly targeting U.S. Patent 8,623,826 has been publicly documented, patent challenges are common in this space. Challenges often involve universities and smaller biotech companies asserting patent invalidity based on prior art.
Key Cases & Disputes:
- No public records of disputes over this patent specifically.
- Similar kinase inhibitor patents have faced validity challenges, often focusing on prior public disclosures.
Patentability and Freedom to Operate Considerations
The claims remain valid against prior art referencing similar heterocycle derivatives, given their specific structural features and claimed methods. However, the wide proliferation of kinase patents necessitates diligence in freedom-to-operate analyses.
Key elements for freedom to operate:
- Careful assessment of patented compounds with similar core structures.
- Monitoring of recent patent applications filed after 2014 that could threaten claim scope.
- Examination of patent expiration dates to identify potential market entry points.
Conclusions
U.S. Patent 8,623,826 protects a specific set of heterocyclic kinase inhibitors with defined structural features and methods of use in cancer therapy. Its claims are moderately broad within the scope of kinase inhibitor development but specific enough to avoid immediate overlap with larger patent families. The patent landscape remains dynamic with extensive filings; practitioners and firms must conduct comprehensive freedom-to-operate analyses for related compounds.
Key Takeaways
- Patent 8,623,826 grants protection for specific heterocyclic kinase inhibitors, primarily targeting cancer therapy.
- The patent claims cover compounds, methods of therapy, and formulations, with a focus on structural features.
- The kinase inhibitor patent field is highly competitive, with broad portfolios from major pharmaceutical companies.
- Patent validity remains intact barring successful prior art challenges; freedom-to-operate assessments are advised.
- The patent will likely remain enforceable until its expiration around 2029–2032, depending on patent term adjustments.
FAQs
1. Does Patent 8,623,826 cover all kinase inhibitors?
No. It specifically claims compounds with a heterocyclic core structure and specific substitutions, not all kinase inhibitors.
2. Can biosimilars infringe this patent?
No. Biosimilars are generally not covered unless they contain the patented chemical structure or are marketed as the patented compounds.
3. Are there ongoing patent litigations involving this patent?
None publicly recorded as of the current date.
4. How does this patent compare in scope with European or Asian patents?
Scope varies by jurisdiction; European and Asian counterparts may have narrower or broader claims, requiring jurisdiction-specific analysis.
5. Is this patent likely to be challenged in the future?
Potentially, especially concerning prior art or obviousness arguments as new kinase inhibitors are developed.
References
[1] United States Patent and Trademark Office. (2014). Patent No. 8,623,826. Retrieved from https://patents.google.com/patent/US8623826
